Completed PHASE1 INTERVENTIONAL 3-arm NCT04828265

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

A Phase 1, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Aldafermin in Healthy Adult Male Japanese and Non-Japanese Subjects

Sponsor: NGM Biopharmaceuticals, Inc

Conditions Healthy Male

Interventions Aldafermin

Updated 4 times since 2021 Last updated: Jan 15, 2022 Started: Apr 13, 2021 Primary completion: Jul 6, 2021 Completion: Jul 6, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04828265, this PHASE1 trial focuses on Healthy Male and remains completed. Sponsored by NGM Biopharmaceuticals, Inc, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Feb 2022 — Jul 2024 [monthly]

Completed PHASE1

Status: Not Yet Recruiting → Completed
May 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Apr 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NGM Biopharmaceuticals, Inc

Data source: NGM Biopharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cypress, United States